EC Number   |
Specific Activity Minimum [µmol/min/mg] |
Specific Activity Maximum [µmol/min/mg] |
Reference |
|---|
   2.7.1.105 | -999 |
- |
- |
640281, 640283, 640298, 640318, 640320, 640341, 661569, 661698, 94931 |
| 2.7.1.105 | -999 |
- |
activity recovery after refolding is 90% in the full range of GdnHCl concentrations of 0.1-5.5 M guanidine hydrochloride |
697948 |
| 2.7.1.105 | -999 |
- |
binding of MgATP to an allosteric site provokes inhibition and a dimer-tetramer conversion of the enzyme, mutant generation by successive deletions of up to 10 residues and point mutations at the C-terminal end, elevated KM values for MgATP that fails to show the dimer-tetramer conversion, Y306 required for the quaternary packing involved in the dimer-tetramer conversion, the following residue L307 is crucial for the ternary packing necessary for the catalytic MgATP-binding site, dimer-tetramer conversion can be uncoupled from the conformational changes that lead to the MgATP-induced allosteric inhibition |
692346 |
| 2.7.1.105 | -999 |
- |
diet-induced obesity in transgenic mice, liver and plasma metabolites in transgenic and control mice, human Pfkfb3-specific gene probe used to quantify transgene overexpression by RT-PCR, measurement of fructose 2,6-bisphosphate levels in the liver, immunostaining and gene expression analysis in livers of transgenic and control mice, changes in hepatic gene expression profiles for key gluconeogenic and lipogenic enzymes, accumulation of lipids in periportal cells, gain in weight |
690702 |
| 2.7.1.105 | -999 |
- |
expression analysis in different tumor specimens with high and low malignity grade, RT-PCR and Western blot |
681540 |
| 2.7.1.105 | -999 |
- |
generation of transgenic mice with chronically elevated glycolysis by cardiac-specific overexpression of PFK-2, measurements of metabolites reveal 3fold elevated levels of fructose 2,6-bisphosphate, expression studies by real-time PCR and Western blot analysis, transgene causes significant increase in glycolysis providing acute benefits against hypoxia |
690361 |
| 2.7.1.105 | -999 |
- |
identification and expression of alternative splice variants in different tissue under hypoxia, splice variants different at C-terminal region but catalytical domains of 6-phosphofructo-2-kinase and fructose-2,6-bisphosphatase identical, tissue-specific expression, different induction under hypoxic conditions, role of splice isoforms in cell adaptation to hypoxic conditions discussed |
695235 |
| 2.7.1.105 | -999 |
- |
inhibition of glucose-induced translocation, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) associated with phosphorylation of PFK2 on Ser-32, increase of phosphorylation less than that caused by glucagon, expression of PFK-2 mutant that lacks Ser-32 (PFK2-M) reverses inhibitory effects on glucokinase translocation |
684366 |
| 2.7.1.105 | -999 |
- |
located on chromosome 3, RNAi mutant analyzed, at the end of day, sucrose contents increased in leaves, fructose 6-phosphate 2-kinase activities and fructose 2,6-bisphosphate levels declined, involvement in the regulation of sucrose synthesis by controlling the levels of fructose 2,6-bisphosphate during the daytime |
681609 |
| 2.7.1.105 | -999 |
- |
monomer structure and structural features of intersubunit interactions, interactions with ligands at the active site, structure determination in its inhibited tetrameric form, with each subunit bound to two ATP molecules and two Mg ions, allosteric site reported for ATP, analogous structural features in the 6-phosphofructokinases from Escherichia coli compared |
693665 |
